The results of the study were announced at a recent media briefing at the Waco facility, during which, Allergan’s President and CEO, Brent Saunders reportedly commented that the plant may be the production site for several new products currently in the pipeline.
According to WacoTrib.com, the company is considering a “big” expansion of the Waco facility, which it called its “flagship” plant for Allergan’s operations in the US.
"As a partner in the Waco and Central Texas communities for 27 years, we are very proud of the significant impact Allergan has had on the local and regional economies here. Our 750 colleagues in Waco have played an important role in bringing important medicines to patients in 110 countries," said Saunders as part of the study results.
A previously announced investment of more than $50m is currently in its final phases and will increase pharmaceutical development and production facilities at the Waco plant, in addition to adding new sterile production lines.
The report also predicted that the total economic impact of Allergan’s investments will reach $450.3m in 2016.
Bryan Daniel, Economic Development and Tourism Division Director for the Office of Governor Greg Abbott, said "I am confident that Texas' extraordinary business climate will continue to attract healthcare industry leaders like Allergan to the Lone Star State."
According to the Tribune, the facility’s close proximity to several educational institutions, including Baylor University, who conducted the economic impact study, is one reason Allergan may consider the site for possible expansion.
"Our rich history and impact in Waco and Central Texas has not been achieved alone,” said Saunders. “It has been made possible by the strong mix of highly skilled and talented people, access to and collaboration with respected health care professionals and medical institutions like Baylor University and the unwavering support of local, state and federal elected officials and trade associations."